5 FDA Decisions for Primary Care to Know from May 2026

In May, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning diabetes care, hypertension, infectious disease, kidney disease, and neuropsychiatric treatment. The following list highlights 5 key updates for primary care, including a pediatric expansion for an inhaled mealtime insulin, approval of a first-in-class hypertension therapy, and the first FDA-approved treatment for chronic hepatitis delta virus infection.